Peter Carlisle Appointed as Director

SYDNEY, Australia and MINNEAPOLIS, Jan. 22, 2018 --

Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF) announces that Mr. Peter Carlisle has been appointed to the Board of Directors of Medibio.  

Peter Carlisle serves as Managing Director of Olympics and Action Sports at the global sports marketing agency, Octagon.  Mr. Carlisle oversees an international business focused on athlete brand-building through commercial, public relations, and cause-related activities.  He has served on numerous non-profit boards and has worked to develop and promote programs focused on a variety of mental health issues.  He has more than 20 years of experience in the sports marketing industry, and has received numerous awards and recognitions, including being one of only two sports agents named to SportsBusiness Journal’s “Forty Under 40” Hall of Fame and its 20 most influential people in action sports.  Sporting News included him in its Power 100 list and Sports Illustrated named him as one of the top 15 most-influential sports agents.  Mr. Carlisle has been named one of the best lawyers in America in sports law on several occasions, and was recognized as Sports Law Lawyer of the Year in 2012.  He has also served as Adjunct Professor of Sports Law at the University of New Hampshire and Maine School of Law, as an attorney at Preti Flaherty, and earned his Juris Doctor from the University of Maine School of Law and Bachelor of Arts from Bates College. 

Mr. Carlisle has dedicated his career to advocating for athletes and has witnessed firsthand the prevalence of mental health issues among elite athletes, the extent to which those issues are overlooked, and the profound need for increased awareness and education and improved treatment and support.

Medibio Chairman Chris Indermaur said, “We sincerely welcome Peter’s appointment to the board of Medibio and look forward to his continued contribution as the company progresses its unique mental health technology.  I am confident that this addition will be warmly welcomed by all our shareholders.”

Mr. Carlisle was previously appointed to the Medibio Board of Directors on June 5, 2017 and was serving as an alternate to Mr. Michael Phelps. 

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:                                                       

Website: www.medibio.com.au

Medibio Shareholder Enquiries:
Stephanie Ottens
Investor Relations Director
Medibio Limited
[email protected]
T: +61 434 405 400

Australian Media Enquiries:
Peter Taylor
NWR Communications
[email protected]
T: +61 (0) 412 036 231